Department of Clinical Oncology, Leeds Cancer Centre, Leeds, UK.
Department of Clinical Oncology, Leeds Cancer Centre, Leeds, UK.
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):e1-e8. doi: 10.1016/j.clon.2019.06.010. Epub 2019 Jul 8.
To assess the impact of weekly scheduled peer review of radiotherapy planning contours for definitive treatment of haematological malignancies based on rates of recommended changes.
Analysis of a prospective database of contour-based peer review at weekly scheduled meetings for patients undergoing definitive radiotherapy for haematological malignancies at a single large cancer centre between January and December 2018. Recommended changes were prospectively classified as involving the gross tumour volume (GTV), clinical target volume (CTV), planning target volume (PTV), organs at risk or dose fractionation. A univariate analysis was carried out to explore the associations between recommended changes and disease, treatment characteristics and consultant experience.
In total, 158/171 (92%) of all cases of haematological malignancy undergoing definitive radiotherapy were prospectively peer reviewed over a 12-month period. Overall, 26/158 (16.5%) changes were recommended within the peer review meetings. This included a total of 27 contour changes (GTV, CTV or PTV) in 25 patients. An increase in CTV was the most common change, occurring in 20/158 (12.7%) cases. One dose-fractionation change was recommended. Additional advice regarding planning technique/set-up was documented in 5/158 (3.2%) patients. There were no significant associations between rates of recommended change and disease type, stage, prior chemotherapy, first line versus refractory/relapse, anatomical site, radiotherapy technique or consultant experience.
Weekly contour-based peer review meetings resulted in a high rate of recommended changes. Compliance was high. Peer review was potentially beneficial for all disease and treatment characteristics and for any degree of clinician experience.
评估每周计划的血液恶性肿瘤根治性放疗计划轮廓同行评审对推荐变更率的影响。
分析了 2018 年 1 月至 12 月期间,在单一大型癌症中心,对接受根治性放疗的血液恶性肿瘤患者,每周在计划会议上进行基于轮廓的同行评审的前瞻性数据库的分析。前瞻性地将推荐的变更分为涉及大体肿瘤体积(GTV)、临床靶区(CTV)、计划靶区(PTV)、危及器官或剂量分割的变更。进行了单变量分析,以探讨推荐的变更与疾病、治疗特征和顾问经验之间的关系。
在 12 个月期间,共对 171 例血液恶性肿瘤根治性放疗中的 158 例(92%)进行了前瞻性同行评审。总体而言,在同行评审会议上推荐了 26/158(16.5%)的变更。这包括 25 名患者共 27 次轮廓变更(GTV、CTV 或 PTV)。CTV 的增加是最常见的变更,发生在 158 例中的 20 例。推荐了一次剂量分割的变更。在 158 例中记录了 5 例(3.2%)患者关于计划技术/设置的额外建议。推荐变更率与疾病类型、分期、化疗前、一线与难治/复发、解剖部位、放疗技术或顾问经验之间无显著相关性。
每周基于轮廓的同行评审会议导致了较高的推荐变更率。合规性很高。同行评审对所有疾病和治疗特征以及任何程度的临床医生经验都可能有益。